Study 3

TITLE

[Contraception in androgenised women with a low-dose cyproterone-acetate containing one-phase preparation (author’s transl)]. Die kontrazeptive Betreuung androgenisierter Frauen mit einem niedrig dosierten cyproteronacetathaltigen Einphasenpraparat.

AUTHOR
Moltz L; Meckies J; Hammerstein J

SOURCE
Dtsch Med Wochenschr 1979 Sep 28; 104 (39): 1376-82

LANGUAGE OF PUBLICATION
German (1350-)

ABSTRACT
101 hirsute women received Diane, a combination of 2 mg cyproterone acetate and 50 micrograms ethinyl oestradiol per capsule, from the fifth to twenty-fifth day during a total of 1105 cycles. The treatment was satisfactory in 96% of women with acne, 84% with androgenic alopecia, 79% with seborrhoea, and 50% of those with mild or moderate hirsutism. The effectiveness of treating hirsutism or alopecia depended on its severity and duration. There was no correlation between various measures of androgen levels before and during treatment and the clinical results. Side effects were similar to those after contraceptive one-phase preparations, both in kind and incidence. None of the women became pregnant. Diane is thus the drug of choice in hormonal contraception of patients with acne, seborrhoea, androgenic alopecia or mild hirsutism. It is also suitable in the follow-up or interval management of high-dose cyproterone acetate treatment of severe hirsutism, in order to maintain the effect obtained with lower hormone doses. (AUTHOR)

MJTR: Contraception. Cyproterone TU.

MNTR: Acne Vulgaris DT. Alopecia DT. Dermatitis, Seborrheic DT. English Abstract. Ethinyl Estradiol. Female. Hirsutism DT. Human. JOURNAL ARTICLE

GEOT: GERMANY, WEST

IDEN: ISSN: 0012-0472. JOURNAL-CODE: ECL. ENTRY-DATE: 791128. JOURNAL-SUBSET: M. IM-DATE: 8001.

ACCE: 80003384